Abstract
Uveitic (or inflammatory) macular edema (UME) is one of the most common cause of visual impairment in patients with uveitis and the most frequent structural complication of uveitis. The use of antiangiogenic agents in the management of macular edema due to inflammation is a fairly new approach. It is not entirely clear if these agents should be used as an adjunct to anti-inflammatory therapy or if they can be used as stand-alone agents in edema due to infections where immunosuppressive therapy could be detrimental to the resolution of infection. This treatment paradigm is largely borrowed from large randomized trials in other retinovascular diseases. Similar prospective studies are needed to clarify the role of antiangiogenic therapy in UME.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
